Sumary of Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia:
- Back to Healio Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.
- Blaser, MD, PhD, assistant professor of leukemia research at The Ohio State University Comprehensive Cancer Center, told Healio.
- Blaser and colleagues assessed the safety and efficacy of a four-dose regimen of 20 mg/kg ficlatuzumab given 14 days apart in combination with high-dose cytarabine in a cohort of 17 patients (median age, 58 years;
- Secondary objectives included the rate of complete remission, PFS and OS. Researchers assessed response through next-generation sequencing with the ARUP Myeloid Malignancies Mutation panel and minimal residual disease using the University of Washington multiparameter flow cytometry assay.
- Results showed the ficlatuzumab-chemotherapy combination induced an overall response rate of 53%, with all responders experiencing complete remission and four having no signs of minimal residual disease.
- Eight responders and two nonresponders underwent hematopoietic stem cell transplantation, of whom six remained in remission at last follow-up.
- Researchers additionally examined peripheral blood mononuclear cells pooled at baseline and at various other timepoints during the study.
- ” Ficlatuzumab could be a treatment option for patients with relapsed or refractory AML if larger randomized studies confirm its efficacy, according to Bradley.